Skip to Content

Press Releases

Press Releases

Mar 16 2021
Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K
JERUSALEM , March 16, 2021 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that it has filed its annual report on Form 10-K for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission .
Mar 15 2021
Intec Pharma and Decoy Biosystems Announce Merger Agreement
Combined Company to Advance Novel Immunotherapy Technology that Primes Both Innate and Adaptive Immune Responses, Targeting Multiple Tumor Types and Chronic Viral infections Investigational New Drug Application Filing Expected in 2H 2021 JERUSALEM , March 15, 2021 /PRNewswire/ -- Intec Pharma Ltd.
Dec 09 2020
Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma
JERUSALEM , Dec. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a feasibility agreement with GW Research Limited ("GW"), London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.  "We
Nov 05 2020
Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update
JERUSALEM , Nov. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update.  "We maintain our focus on executing strategic partnerships and collaborations.
Oct 29 2020
Intec Pharma Announces 1-for-20 Reverse Share Split
JERUSALEM , Oct. 29, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020 , and the
Oct 08 2020
Intec Pharma Announces New Research Collaboration Agreement with MSD
JERUSALEM , Oct. 8, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ , USA. Details of the agreement are confidential.
Sep 14 2020
Intec Pharma to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
JERUSALEM , Sept. 14, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date:
Sep 08 2020
Intec Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference
JERUSALEM , Sept. 8, 2020 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the virtual H.C. Wainwright 22 nd Annual Global Investment Conference . H.C. Wainwright 22 nd Annual Global Investment Conference Date:
Aug 07 2020
Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering
JERUSALEM , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital Fund (“Aspire”) for the purchase and sale, in a registered direct offering, of 7,125,000 of the Company’s
Aug 05 2020
Intec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
JERUSALEM , Aug. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the second quarter ended June 30, 2020 and provides a corporate update.  "We have worked diligently over the past quarter to address the challenges of an
Displaying 1 - 10 of 119